对抗疟疾药物卡巴米基因选择突变寄生虫的倾向
Eva Stadler1, Mohamed Maiga2, Lukas Friedrich3
1The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
Nature communications
|August 25, 2023
概括
抗疟疾药物卡巴米奎因可以选择耐药的Plasmodium falciparum寄生虫. 在多个模型中发现了耐药性突变,这表明先前存在的耐药性Plasmodium falciparum菌株.
科学领域:
- 寄生虫学的寄生虫学
- 药物耐药性 药物耐药性 药物耐药性
- 分子生物学分子生物学
背景情况:
- 抗疟疾药物耐药性是全球主要的健康挑战.
- 卡巴米奎因是一种特定于Plasmodium的真核延长因子2的抑制剂.
- 了解耐药机制对于开发有效的抗疟疾疗法至关重要.
研究的目的:
- 分析卡巴米奎因对抗性Plasmodium falciparum的选择倾向.
- 识别和描述与耐药性相关的突变.
- 调查耐药性Plasmodium falciparum的存在和发生频率.
主要方法:
- 使用实验室菌株和临床分离物的体外研究.
- 在人性化的小鼠模型中进行感染研究.
- 志愿者感染研究.
- 数学和结构建模.数学和结构建模.
主要成果:
- 在Plasmodium falciparum中的11个氨基酸位置确定了与耐药性相关的突变.
- 在不同的感染模型中,一致发现了6种突变 (55%).
- 数学建模表明在药物暴露时已经存在的耐药突变物.
- 结构建模表明,卡巴米奎因与抵抗突变附近的浅层mRNA部位结合.
结论:
- 卡巴米奎因选择耐药的虫寄生虫.
- 识别的耐药性突变可以在各种感染模型中翻译.
- 耐药的Plasmodium falciparum突变可能已经存在.
- 药物结合部位和抗性突变提供了对抗性机制的洞察力.
相关概念视频
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...